NCT03500731View on ClinicalTrials.gov

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Idiopathic Pulmonary FibrosisEmphysema or COPD
Interventions
BIOLOGICAL

CD3/CD19 negative hematopoietic stem cells

Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

DRUG

Rituximab

Transplantation Conditioning

DRUG

Alemtuzumab

Transplantation Conditioning

DRUG

Fludarabine

Transplantation Conditioning

DRUG

Thiotepa

Transplantation Conditioning

DRUG

G-CSF

Transplantation conditioning

DRUG

Hydroxyurea

Transplantation Conditioning

Trial Locations (2)

15214

RECRUITING

UPMC Presbyterian, Pittsburgh

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

All Listed Sponsors
lead

Paul Szabolcs

OTHER